Status:
TERMINATED
A Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration for Research Purposes
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Ependymomas
Gliomas
Eligibility:
All Genders
18-100 years
Brief Summary
Background: \- An important new area of brain tumor research is the development of tumor and brain stem cell lines. Successful growth of these cell lines requires obtaining large volumes of fresh tum...
Detailed Description
BACKGROUND: \- Patients treated by the Neuro-Oncology Branch (NOB) for their brain tumors unfortunately and commonly succumb to their disease. They and their loved ones often seek a way of adding mea...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Patients with primary brain tumors including glioblastoma multiforme (GBM), gliosarcoma (GS), anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), anaplastic mixed oligoastrocytoma (AMO), low grade astrocytoma, low grade oligoastrocytoma, low grade oligodendroglioma, astrocytoma NOS (not otherwise specified), radiographically diagnosed brain stem gliomas, primitive neuroectodermal tumors (PNETs, including medulloblastomas, supratentorial PNET), pineal tumors, glioneuronal tumors, ependymomas and primary central nervous system lymphomas.
- All patients or their LAR (Legally Authorized Individual) (if the patient is deemed by the treating physician to be impaired or questionably impaired in such a way that the ability of the patient to give informed consent is questionable) must sign an informed consent indicating that they are aware of the investigational nature of this study.
- Patients or their LAR and their legal next of kin must agree to a Do Not Resuscitate order and Consent for Autopsy as part of the end-of-life care plan.
- Patients must be greater than or equal to 18 years old, and with a life expectancy \< two weeks.
- This study was designed to include women and minorities, but was not designed to measure differences of intervention effects. Males and females will be recruited with no preference to gender. No exclusion to this study will be based on race. Minorities will actively be recruited to participate.
- EXCLUSION CRITERIA:
- Known to be pregnant (known positive pregnancy test although such testing is not a requirement for enrollment).
- HIV-positive patients or those suspected of infectious cerebritis/abscess are ineligible because of the potential for contamination of brain tissue.
Exclusion
Key Trial Info
Start Date :
November 12 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 29 2015
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT01251913
Start Date
November 12 2010
End Date
April 29 2015
Last Update
December 3 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892